Approval · Notice of Compliance 29396 · 2022
ACTONEL: Notice of Compliance 29396
Issued November 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29396
- Date
- November 4, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Merger/Buy-out
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | 02246896 | Marketed |
| ACTONEL | 02316838 | Marketed |
| ACTONEL DR | 02370417 | Marketed |
Medicinal ingredients
- RISEDRONATE SODIUM 35 MG per TAB
- RISEDRONATE SODIUM 150 MG per TAB